Ground News

institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Novo Nordisk image

News about Novo Nordisk

Stay current with all the latest and breaking news about Novo Nordisk, compare headlines and perspectives between news sources on stories happening today. In total, 135stories have been published about Novo Nordisk which Ground News has aggregated in the past 3 months.

Covered Most By

Team Novo Nordisk

Suggest a source

Local News Publishers

Suggest a source

Looking for a source we don't already have? Suggest one here.

Top Novo Nordisk News

Novo Nordisk ends deal with Hims & Hers over sales of Wegovy copycats; HIMS drops 20%

Novo Nordisk · United States

Novo Nordisk ends deal with Hims & Hers over sales of Wegovy copycats; HIMS drops 20%

62% Center coverage: 73 sources

Collaboration of over one month has ended based on Hims & Hers deceptive promotion and selling of illegitimate, knockoff versions of Wegovy® that put patient...See the Story

Eli Lilly's Oral GLP-1 Pill Matches Injectables, Eyes Approval by Year-End

Pharma · United States

Eli Lilly's Oral GLP-1 Pill Matches Injectables, Eyes Approval by Year-End

64% Center coverage: 40 sources

Data on Novo Nordisk experimental weight-loss drug show mostly mild side effects

Novo Nordisk · Denmark

Data on Novo Nordisk experimental weight-loss drug show mostly mild side effects

76% Center coverage: 33 sources

Novo Nordisk on Sunday said full results from two late-stage trials of its experimental weight-loss drug CagriSema show that side effects were mainly mild-to-moderate and other outcome results, including blood sugar levels, were positive. The company had previously announced top-line results for the 68-week studies, which found that CagriSema led to nearly 23% weight loss for overweight or obese adults, while overweight type 2 diabetics lost nearly 16% of their weight. Those results, however, disappointed investors, sending Novo's shares lower. The company last month ousted its CEO Lars Fruergaard Jorgensen.See the Story

Patients deserve easy access to innovative obesity drugs

89% Center coverage: 27 sources

Insulin changed the way we treat and manage diabetes. Chemotherapy has precipitously reduced the mortality rate of certain cancers.Obesity · College Station See the Story

Study Claims Ozempic May Also Help Reduce Dementia Risk

50% Center coverage: 18 sources

Researchers found that the active ingredient in Ozempic may lower the risk of dementia in people with type 2 diabetes.Alzheimer's Disease See the Story

Swiss insurers fear cost explosion from weight loss drug

Since March 2024, Switzerland’s basic health insurance started reimbursing part of the cost of Wegovy, a weight-loss drug developed by Danish pharmaceutical giant Novo Nordisk. The decision has led to a surge in uptake—and concern among insurers, reported RTS. Roughly 40,000 people received Wegovy under Switzerland’s mandatory health insurance in 2024, according an association representing […]Wegovy · Switzerland Read Article

Harbour Trust & Investment Management Co Purchases 22,195 Shares of Novo Nordisk A/S (NYSE:NVO)

100% Center coverage: 1 sources

Harbour Trust & Investment Management Co boosted its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 26.1% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 107,261 shares of the company's stock after purchasing an additional 22,195 shares duNovo Nordisk · Denmark Read Article

Novo Nordisk A/S (NYSE:NVO) Receives Consensus Recommendation of "Hold" from Analysts

100% Center coverage: 1 sources

Novo Nordisk A/S (NYSE:NVO - Get Free Report) has earned a consensus recommendation of "Hold" from the eleven research firms that are presently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating, three have givenNovo Nordisk · Denmark Read Article

How Novo Nordisk Misread the US Market for Its Weight Loss Sensation – RamaOnHealthcare

COPENHAGEN (Reuters) -Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of itsPharma · Denmark See the Story

Lot of diabetes, weight loss drug Ozempic recalled in Canada

Coverage: 2 sources

Novo Nordisk Canada has issued a voluntary recall for a lot of its semaglutide injection pens Ozempic due to potential cracked glass cartridges. The recalled cartridge strength is 1mg 3mL and its lot number is RZFFE55.Health Canada · Canada See the Story

Notable healthcare headlines for the week: Novo Nordisk, Amgen and UnitedHealth in focus

100% Right coverage: 1 sources

Learn more about Novo Nordisk A/S (NVO). From their employee growth over the years and their exchange listings.Amgen See the Story

Breaking News Topics Related to Novo Nordisk